ArticleUrologic oncology2016
Commentary on "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer." Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38.
Article in Urologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2023Pooled it
- Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.Future science OA · 2025Review
- Liquid biopsy: paving a new avenue for cancer research.Cell adhesion & migration · 2024Review
- Marine Natural Products with Activities against Prostate Cancer: Recent Discoveries.International journal of molecular sciences · 2023Review
- Review
- Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.Cancer gene therapy · 2022Article
- Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments.Molecular cancer · 2022Review
- Circular RNAs in prostate cancer: Biogenesis,biological functions, and clinical significance.Molecular therapy. Nucleic acids · 2021Review
- Immune Checkpoint Inhibitors in Prostate Cancer.Cancers · 2021Review
- Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.Investigational new drugs · 2018Review
- Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.Current treatment options in oncology · 2018Review
- AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?World journal of urology · 2018Article
- RNA splicing and splicing regulator changes in prostate cancer pathology.Human genetics · 2017Review
- Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis.Prostate cancer · 2017Article
- Androgen receptor aberrations in the era of abiraterone and enzalutamide.World journal of urology · 2016Review
- Review
- AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.Investigational new drugs · 2015Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26964769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.